Gemfibrozil is a compound which lowers the concentration of serum triglycerides in the rat (Rodney et al. 1976 ) as well as in man (Smith 1976 , Olsson et al. 1976 . We have recently seen that gemfibrozil lowers the triglyceride content, particularly that of the very low density lipoproteins but also that of low density and high density lipoproteins (Olsson & Carlson 1976) .
A compound which lowers the concentration of plasma triglycerides may do so either by decreasing the synthesis of the triglyceride-rich very low density lipoproteins from the liver, or by increasing the clearance of triglycerides from these lipoproteins in the plasma. The adipose tissue may play a regulatory role with regard to both these mechanisms.
An increased clearance from the blood of lipoprotein-bound triglycerides may occur if the lipoprotein lipase activity in one way or another is raised. This enzyme system is believed to be responsible for the hydrolysis of the circulating lipoprotein triglycerides (Robinson 1970 ). Another possibility is that an increase of the fatty acid incorporation into adipose tissue (FIAT) process may be stimulated. We have recently observed that the FIAT process is significantly reduced in subjects with different kinds of hypertriglyceridemia (Carlson & Walldius 1976 , Walldius 1976 .
On the other hand, the adipose tissue may also play a significant role in the synthesis of the triglyceride-rich lipoproteins from the liver, by provision of free fatty acids (FFA). FFA mobilized from adipose tissue are to a large extent taken up by the liver, and, among other things, they act there as precursors to the very low density lipoprotein (VLDL) triglycerides.
An important factor controlling the rate of mobilization of FFA from adipose tissue is the fat-mobilizing lipolysis. This process regulates the breakdown of the adipose tissue triglycerides into fatty acids which are then mobilized into the blood stream where they occur as albuminbound FFA.
We have earlier summarized and discussed the relation between stimulation of lipolysis and hypertriglyceridwmia, and on the other hand the inhibition of fat-mobilizing lipolysis and reduc-Professor L A Carlson tion of circulating triglyceride levels. It has earlier been shown that two lipid lowering compounds, nicotinic acid (Carlson 1963 ) and clofibrate (Carlson et al. 1972 ) inhibit fatmobilizing lipolysis in adipose tissue and also lower the concentration of circulating FFA (Carlson & Oro 1962 , Macmillan et al. 1965 ). Against the above background it was considered important to study in vitro the effect of gemfibrozil on fat-mobilizing lipolysis in human adipose tissue.
Materials and Methods
Human adipose tissue was obtained during surgery for non-acute gall-bladder disease. The patients were fasting and had received only i.v. saline before the tissue was taken. The tissue was immediately put into a Krebs-Ringer bicarbonate buffer, pH 7.4, at room temperature, containing 2% human albumin. It usually arrived in the laboratory within 15 min. It was then immediately dissected free from visible connective tissue, cut into pieces 20-40 mg in weight, and four pieces were added to incubation flasks containing 1 ml of Krebs-Ringer bicarbonate buffer with 0.1 % glucose and 2 % human albumin (Kabi).
After pre-incubation for about 30 min at room temperature, the various additions were made as indicated in Tables 1-4, and 0.5 ml of medium was taken off for initial enzymatic analysis of glycerol. The additions were made by adding Table 1 Effect of gemfibrozil and clofibrate on basal and on noradrenaline-stimulated lipolysis in seven specimens of rat epididymal fat incubated in vitro (mean ± s.e.)
Basal Noradrenaline
Gemfibrozil
Lipolysis was determined as release of glycerol into the incubation medium. Noradrenaline concentration was I sg/ml * P < 0.001 (Statistical significance of the difference against the condition without added agents) Table 2 Effect of gemfibrozil and clofibrate on basal and on noradrenaline-stimulated lipolysis in human omental adipose tissue from 4 different subjects incubated in vitro (mean ± s.e.)
Basal Nordarenaline Table 3 Effect of gemfibrozil and clofibrate on isoprenaline.
(1 xLg/ml) and on theophylline-(10-'M) stimulated lipolysis in six specimens of human omental adipose tissue (mean ± s.e.)
Isoprenaline Theophylline
Gemfibrozil release of glycerol was then calculated per g of tissue. The weight of adipose tissue was obtained by weighing the incubation vessels before and after adipose tissue pieces were added. Rat fat was obtained from male Sprague-Dawley rats weighing approximately 180 g. The rats had free access to food and water. They were decapitated at 9.00 a.m. and their epididymal fat pads were cut into pieces and randomized into incubation flasks as described previously (Bizzi & Carlson 1965) . Otherwise, the procedure was as described above for human fat.
Results
Gemfibrozil and clofibrate invariably inhibit basal as well as noradrenaline stimulated fatmobilizing lipolysis in rat fat. One typical experiment is shown in Table 1 . Both gemfibrozil and clofibrate inhibited the basal lipolysis by a little more than 50 %. Noradrenaline-stimulated lipolysis was inhibited almost 50% by gemfibrozil and about 25 % by clofibrate.
While the inhibition of fat-mobilizing lipolysis was a consistent and reproducible finding in rat fat, variable results were obtained in experiments from day to day with both gemfibrozil and clofibrate. Table 2 shows that there was very little inhibition of basal lipolysis by these two compounds in the four experiments recorded. On the other hand when lipolysis had been stimulated by noradrenaline, gemfibrozil showed significant inhibition of lipolysis in two out of four experiments, while clofibrate reduced lipolysis in three of the four experiments. Table 3 shows that both gemfibrozil and clofibrate inhibited fat-mobilizing lipolysis stimulated by isoprenaline to about the same extent. On the other hand, in the same adipose tissue, neither of the compounds inhibited the theophylline-stimulated lipolysis.
A typical dose-response study is given in Table 4 . It can be seen that neither 10 nor 100 ,g/ml of incubation medium of either compound was sufficient to induce inhibition of fatmobilizing lipolysis. For both compounds, inhibition of noradrenaline-stimulated lipolysis did not occur until the medium concentration increased to 1000 ,Fg/ml of incubation medium.
Discussion
As in many instances, rat and human fat behaved differently in vitro. In this study, this difference was mainly of a quantitative nature, as fat from both species responded with inhibition of lipolysis to the two plasma lipid lowering compounds, gemfibrozil and clofibrate. The difference between the two species was mainly that rat fat responded more readily. This may in part be due to the more intense basal and noradrenaline-stimulated rate of fat-mobilizing lipolysis in this species.
As stated in the introduction, a reduction in the amount of FFA reaching the liver may lower the synthesis of VLDL and thereby cause a reduction of the concentration of plasma triglycerides. The present finding that gemfibrozil and clofibrate inhibited fat-mobilizing lipolysis in vitro may therefore suggest that the plasma triglyceride lowering of these compounds is due to a reduction in the synthesis of plasma triglycerides in the liver.
However, it has recently been shown that when fat-mobilizing lipolysis in adipose tissue is inhibited, this leads to a stimulation of the FIAT process (Walldius 1976 ). It has also been demonstrated and discussed in detail by Robinson & Wing (1970) that there is also a reverse relationship between the rate of fat-mobilizing lipolysis and lipoprotein lipase activity in adipose tissue.
It is therefore possible that the two lipid lowering compounds may not only reduce mobilization of FFA from adipose tissue but may also stimulate lipoprotein lipase activity as well as the FIAT process, and thereby cause a stimulation of the clearance of plasma triglycerides. The lowering of the plasma triglyceride concentration by the two studied compounds might thus be due to a combination of an effect on synthesis as well as on elimination rate. However, the possibilities of increased lipoprotein lipase activity and increased FIAT activity must await further direct studies.
Furthermore, a word of caution on the pharmacological implication of the present findings is certainly needed. To reach the effect, fairly high concentrations (of the order of magnitude of 1000 ,ug/ml of plasma) were needed for both compounds. Particularly with regard to gemfibrozil, this is about 50-100 times the concentration which is reached when patients are treated with this compound (Okerholm et al. 1976) . The concentration of clofibrate during treatment with this compound, however, reaches higher levels, from 50 to 100 mg/100 ml. Therefore one cannot extrapolate from the present in vitro to in vivo conditions with regard to the action of gemfibrozil. It would however be of considerable interest to study fat-mobilizing lipolysis as well as lipoprotein lipase activity, and the FIAT process in patients before and during treatment with this compound.
Summary
Fat-mobilizing lipolysis was studied in rat and human adipose tissue during incubation in vitro by following the release of glycerol into the incubation medium. Gemfibrozil as well as clofibrate consistently and readily inhibited basal as well as noradrenaline-stimulated fat-mobilizing lipolysis in rat fat.
With human adipose tissue no effect was observed with gemfibrozil and clofibrate on basal lipolysis. This may be due to the comparatively low rate of the nonstimulated fat-mobilizing lipolysis in human tissue incubated in vitro. When lipolysis was stimulated with noradrenaline as well as isoprenaline, however, both gemfibrozil and clofibrate significantly reduced the fatmobilizing lipolysis. This inhibition of lipolysis was however not observed in all studies. When lipolysis had been stimulated with theophylline, no inhibition of lipolysis was obtained with either compound.
The possibility that reduced fat-mobilizing lipolysis in adipose tissue may cause a lowering of plasma triglycerides by reducing the flow of FFA to the liver is discussed in some detail. It is also suggested that inhibition of lipolysis may be accompanied by increased activity of lipoprotein lipase as well as an increase in the FIAT process.
However, the pharmacological implication of the above-mentioned findings, particularly for gemfibrozil, must await further studies, as fairly large doses, around 1 mg/ml of incubation medium, were needed to obtain inhibition of fat-mobilizing lipolysis.
